Comparable stake leader
JPMORGAN CHASE & CO
SEC ownership of ALTERITY THERAPEUTICS LTD
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001131343.
Disclosed value leader
MORGAN STANLEY
Comparable rows
1/27
Latest evidence
30 Jun 2026
- Public ticker
- ATHE on Nasdaq, PRNAF on OTC
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
JPMORGAN CHASE & CO
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
1 of 27
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
JPMORGAN CHASE & CO
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001131343
- Issuer location
- Melbourne
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of ALTERITY THERAPEUTICS LTD (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
JPMORGAN CHASE & CO
Disclosed value leader
MORGAN STANLEY
Comparable rows
1/27
Latest evidence
30 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 4%
26 rows are not safely comparable across share classes.
13D/G row: JPMORGAN CHASE & CO
Showing 1-8 of 27 holder rows.
Quick read
JPMORGAN CHASE & CO leads the comparable SEC ownership view at 4%.
1 of 27 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens JPMORGAN CHASE & CO's linked filing trail.
Comparable ownership
Top 1
JPMORGAN CHASE & CO
4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 27 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| JPMORGAN CHASE & CO |
13D/G
|
4%
|
—
366,034,937 shares
|
$0 | 30 Apr 2025 |
| MORGAN STANLEY |
13F
Company
|
—
class O/S missing
|
$338,660
63,065 shares
|
— | 30 Jun 2026 |
| GREENLEAF TRUST |
13F
Company
|
—
class O/S missing
|
$332,940
62,000 shares
|
— | 30 Jun 2026 |
| HB Wealth Management, LLC |
13F
Company
|
—
class O/S missing
|
$313,930
58,460 shares
|
— | 30 Jun 2026 |
| CITADEL ADVISORS LLC |
13F
Company
|
—
class O/S missing
|
$201,896
37,597 shares
|
— | 30 Jun 2026 |
| HRT FINANCIAL LP |
13F
Company
|
—
class O/S missing
|
$92,000
17,292 shares
|
— | 30 Jun 2026 |
| BNP PARIBAS FINANCIAL MARKETS |
13F
Company
|
—
class O/S missing
|
$54,983
10,239 shares
|
— | 30 Jun 2026 |
| GAMMA Investing LLC |
13F
Company
|
—
class O/S missing
|
$12,399
2,309 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 18 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-6 of 6 reporting-owner rows connected to ALTERITY THERAPEUTICS LTD. Open a relationship link for the CIK-to-CIK filing trail.
Rows
6
Largest Forms 3/4/5 holder
Peter Ashley Marks
Net 12M change
$0
Latest report
15 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Peter Ashley Marks | Director | Mixed | 10 Apr 2026 | |||
| Niven Abby Sarah Macnish | Chief Financial Officer | Mixed | 09 Apr 2026 | |||
| Julian Michael Babarczy | Director | Mixed | 15 Jun 2026 | |||
| Lawrence Bernard Gozlan | Director | Mixed | 15 Jun 2026 | |||
| David Allen Stamler | Chief Executive Officer, Director | Mixed | 15 Apr 2026 | |||
| Ann Michelle Cunningham | Director | Mixed | 17 Apr 2026 |
Recent insider transactions for ALTERITY THERAPEUTICS LTD
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Julian Michael Babarczy | ATHE | Unlisted option exp 15 Jun 2031 | Award | 2,000,000 | 2,000,000 | 15 Jun 2026 | Vaucluse Investment Holdings Pty Ltd <Jigsaw Investment A/C> | |||
| Lawrence Bernard Gozlan | ATHE | Listed option exp 15 Jun 2031 | Award | 1,000,000 | 1,000,000 | 15 Jun 2026 | Montoya Pty Ltd <Buttercup A/C> |
* marks a reported price that did not pass the local price check.